PDS Planning Inc Buys Shares of 1,153,120 Cybin Inc. (NYSEAMERICAN:CYBN)

PDS Planning Inc bought a new stake in Cybin Inc. (NYSEAMERICAN:CYBN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,153,120 shares of the company’s stock, valued at approximately $473,000. PDS Planning Inc owned 0.28% of Cybin as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Connecticut Wealth Management LLC acquired a new stake in shares of Cybin in the third quarter valued at $28,000. Thrive Wealth Management LLC grew its stake in shares of Cybin by 141.5% in the fourth quarter. Thrive Wealth Management LLC now owns 128,000 shares of the company’s stock valued at $52,000 after buying an additional 75,000 shares in the last quarter. FNY Investment Advisers LLC grew its stake in shares of Cybin by 20,000.0% in the fourth quarter. FNY Investment Advisers LLC now owns 402,000 shares of the company’s stock valued at $164,000 after buying an additional 400,000 shares in the last quarter. Lewis Asset Management LLC acquired a new stake in shares of Cybin in the fourth quarter valued at $116,000. Finally, Cerity Partners LLC grew its stake in shares of Cybin by 488.5% in the fourth quarter. Cerity Partners LLC now owns 88,271 shares of the company’s stock valued at $36,000 after buying an additional 73,271 shares in the last quarter. Hedge funds and other institutional investors own 17.94% of the company’s stock.

Cybin Price Performance

CYBN traded down $0.01 on Tuesday, hitting $0.35. 1,343,678 shares of the company were exchanged, compared to its average volume of 5,112,670. Cybin Inc. has a twelve month low of $0.21 and a twelve month high of $0.74.

Cybin (NYSEAMERICAN:CYBN) last released its earnings results on Wednesday, February 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.04). Research analysts anticipate that Cybin Inc. will post -0.22 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Cybin in a research note on Wednesday, March 13th.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.